Targeting VEGF in Cancer Therapy
Tóm tắt
Từ khóa
Tài liệu tham khảo
Ferrara, 2004, Vascular endothelial growth factor as a target for anticancer therapy, Oncologist, 9, 2, 10.1634/theoncologist.9-suppl_1-2
Hicklin, 2005, Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis, J Clin Oncol, 23, 1011, 10.1200/JCO.2005.06.081
Parikh, 2004, The vascular endothelial growth factor family and its receptors, Hematol Oncol Clin N Am, 18, 951, 10.1016/j.hoc.2004.06.004
Xie, 2004, Constitutive and inducible expression and regulation of vascular endothelial growth factor, Cytokine Growth Factor Rev, 15, 297, 10.1016/j.cytogfr.2004.04.003
DiSalvo, 1995, Purification and characterization of a naturally occurring vascular endothelial growth factor-placenta growth factor heterodimer, J Biol Chem, 270, 7717, 10.1074/jbc.270.13.7717
Ferrara, 2004, Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer, Nat Rev Drug Discov, 3, 391, 10.1038/nrd1381
Dupont, 2004, Phase I and pharmacokinetic study of VEGF Trap administered subcutaneously (sc) to patients (pts) with advanced solid malignancies, Proc Am Soc Clin Oncol, 3009a, 10.1200/jco.2004.22.14_suppl.3009
Konner, 2004, Use of soluble recombinant decoy receptor vascular endothelial growth factor Trap (VEGF Trap) to inhibit vascular endothelial growth factor activity, Clin Colorectal Cancer, 4, S81, 10.3816/CCC.2004.s.013
Dupont, 2005, Safety and pharmacokinetics of intravenous VEGF Trap in a phase I clinical trial of patients with advanced solid tumors, Proc Am Soc Clin Oncol, 3029a, 10.1200/jco.2005.23.16_suppl.3029
Morgan, 2003, Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases, J Clin Oncol, 21, 3955, 10.1200/JCO.2003.08.092
Drevs, 2003, Phase I dose-escalation and pharmacokinetic (PK) study of the VEGF inhibitor PTK787/ZK 222584 (PTK/ZK) in patients with liver metastases, Proc Am Soc Clin Oncol, 1142a
Thomas, 2005, Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer, J Clin Oncol, 23, 4162, 10.1200/JCO.2005.09.034
Hurwitz, 2002, Clinical evaluation of ZD6474, an orally active inhibitor of VEGF signaling, in patients with solid tumors, Proc Am Soc Clin Oncol, 325a
Wilhelm, 2004, BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis, Cancer Res, 64, 7099, 10.1158/0008-5472.CAN-04-1443
Strumberg, 2005, Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors, J Clin Oncol, 23, 965, 10.1200/JCO.2005.06.124
O’Farrell, 2003, SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo, Blood, 101, 3597, 10.1182/blood-2002-07-2307
Mendel, 2003, In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors, Clin Cancer Res, 9, 327
Rosen, 2003, Phase I trial of SU011248, a novel tyrosine kinase inhibitor in advanced solid tumors, Proc Am Soc Clin Oncol, 765a
Martinelli, 2005, AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases, Proc Am Soc Clin Oncol, 3039a, 10.1200/jco.2005.23.16_suppl.3039
Baselga, 2005, Phase I study of AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases, Proc Am Soc Clin Oncol, 3028a, 10.1200/jco.2005.23.16_suppl.3028
Levine, 2004, Phase I trial of anti-sense oligonucleotide vascular endothelial growth factor (VEGF-AS, Veglin) in patients with relapsed and refractory malignancies, Proc Am Soc Clin Oncol, 3008a, 10.1200/jco.2004.22.14_suppl.3008
Takebayashi, 1996, Angiogenesis as an unfavorable prognostic factor in human colorectal carcinoma, Cancer, 78, 226, 10.1002/(SICI)1097-0142(19960715)78:2<226::AID-CNCR6>3.0.CO;2-J
Takahashi, 1995, Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer, Cancer Res, 55, 3964
Lee, 2000, Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients, Eur J Cancer, 36, 748, 10.1016/S0959-8049(00)00003-4
Ellis, 2004, Angiogenesis and its role in colorectal tumor and metastasis formation, Semin Oncol, 31, 3, 10.1053/j.seminoncol.2004.11.028
Fan, 2005, Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells, Oncogene, 24, 2647, 10.1038/sj.onc.1208246
Kabbinavar, 2003, Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer, J Clin Oncol, 21, 60, 10.1200/JCO.2003.10.066
Petrelli, 1989, Modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma, J Clin Oncol, 7, 1419, 10.1200/JCO.1989.7.10.1419
Saltz, 1996, Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors, J Clin Oncol, 14, 2959, 10.1200/JCO.1996.14.11.2959
Hurwitz, 2004, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer, N Engl J Med, 350, 2335, 10.1056/NEJMoa032691
Hurwitz, 2005, Bevacizumab in combination with fluorouracil and leucovorin, J Clin Oncol, 23, 3502, 10.1200/JCO.2005.10.017
Kabbinavar, 2005, Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer, J Clin Oncol, 23, 3697, 10.1200/JCO.2005.05.112
DeGramont, 2000, Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer, J Clin Oncol, 18, 2938, 10.1200/JCO.2000.18.16.2938
Giantonio, 2005, High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer, Proc Am Soc Clin Oncol, 2a, 10.1200/jco.2005.23.16_suppl.2
Reddy, 2005, The addition of bevacizumab to FOLFOX4 prolongs survival in relapsed colorectal cancer, Clin Colorectal Cancer, 4, 300, 10.1016/S1533-0028(11)70131-1
Chen, 2004, Bevacizumab (BV) plus 5-FU/leucovorin (FU/LV) for advanced colorectal cancer (CRC) that progressed after standard chemotherapies, Proc Am Soc Clin Oncol, 3515a, 10.1200/jco.2004.22.14_suppl.3515
Saltz, 2005, Randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer, Proc Am Soc Clin Oncol, 3508a, 10.1200/jco.2005.23.16_suppl.3508
Saltz, 2005, Interim report of randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer, ASCO Gastrointest Cancer Symp, 169b
Klem, 2003, Current studies with PTK787, an oral inhibitor of vascular endothelial growth factor, in colorectal cancer, Clin Colorectal Cancer, 3, 147, 10.1016/S1533-0028(11)70081-0
Tyagi, 2005, Vatalanib (PTK787/ZK 222584) in combination with FOLFOX4 versus FOLFOX4 alone as first-line treatment for colorectal cancer, Clin Colorectal Cancer, 5, 24, 10.1016/S1533-0028(11)70162-1
Andre, 1999, CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR, Eur J Cancer, 35, 1343, 10.1016/S0959-8049(99)00150-1
Trarbach, 2003, Preliminary phase I results of the oral, once-daily angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK) in combination with chemotherapy for the treatment of metastatic colorectal cancer, Eur J Cancer Suppl, 1, S91, 10.1016/S1359-6349(03)90330-2
Steward, 2004, Expanded phase I/II study of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with FOLFOX-4 as first-line treatment for patients with metastatic colorectal cancer, Proc Am Soc Clin Oncol, 3556a, 10.1200/jco.2004.22.14_suppl.3556
Hecht, 2005, A randomized double-blind, placebo-controlled, phase III study in patients with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1), Proc Am Soc Clin Oncol, LBA3, 10.1200/jco.2005.23.16_suppl.lba3
Bukowski, 2001, Cytokine therapy for metastatic renal cell carcinoma, Semin Urol Oncol, 19, 148
Rini, 2005, Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma, J Clin Oncol, 23, 1028, 10.1200/JCO.2005.01.186
Crossey, 1994, Molecular genetic investigations of the mechanism of tumorigenesis in von Hippel-Lindau disease, Hum Genet, 93, 53, 10.1007/BF00218913
Gnarra, 1994, Mutations of the VHL tumour suppressor gene in renal carcinoma, Nat Genet, 7, 85, 10.1038/ng0594-85
Shuin, 1994, Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas, Cancer Res, 54, 2852
Gallou, 1999, Mutations of the VHL gene in sporadic renal cell carcinoma, Hum Mutat, 13, 464, 10.1002/(SICI)1098-1004(1999)13:6<464::AID-HUMU6>3.0.CO;2-A
Maxwell, 1999, The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis, Nature, 399, 271, 10.1038/20459
Cockman, 2000, Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein, J Biol Chem, 275, 25733, 10.1074/jbc.M002740200
Iliopoulos, 1996, Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein, Proc Natl Acad Sci USA, 93, 10595, 10.1073/pnas.93.20.10595
Gnarra, 1996, Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene, Proc Natl Acad Sci USA, 93, 10589, 10.1073/pnas.93.20.10589
Na, 2003, Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1α expression in renal cell carcinomas, J Urol, 170, 588, 10.1097/01.ju.0000074870.54671.98
Turner, 2002, Expression of hypoxia-inducible factors in human renal cancer, Cancer Res, 62, 2957
Yang, 2003, A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer, N Engl J Med, 349, 427, 10.1056/NEJMoa021491
Elaraj, 2004, A pilot study of antiangiogenic therapy with bevacizumab and thalidomide in patients with metastatic renal cell carcinoma, J Immunother, 27, 259, 10.1097/00002371-200407000-00001
Spigel, 2005, Bevacizumab and erlotonib in the treatment of patients with metastatic renal cell carcinoma (RCC), Proc Am Soc Clin Oncol, 4540a, 10.1200/jco.2005.23.16_suppl.4540
Rini, 2004, Cancer and Leukemia Group B 90206, Clin Cancer Res, 10, 2584, 10.1158/1078-0432.CCR-03-0605
George, 2003, Phase I study of PTK787/ZK 222584 (PTK/ZK) in metastatic renal cell carcinoma, Proc Am Soc Clin Oncol, 1548a
Ahmad, 2004, Kinase inhibition with BAY 43-9006 in renal cell carcinoma, Clin Cancer Res, 10, 6388s, 10.1158/1078-0432.CCR-040028
O’Dwyer, 2005, Pharmacodynamic study of BAY 43-9006 in patients with metastatic renal cell carcinoma Proc Am Soc Clin Oncol, 3005a
Ratain, 2004, Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT), Proc Am Soc Clin Oncol, 4501a, 10.1200/jco.2004.22.14_suppl.4501
Han, 2001, Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis, Ann Surg Oncol, 8, 72, 10.1007/s10434-001-0072-y
Fontanini, 2002, A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma, Br J Cancer, 86, 558, 10.1038/sj.bjc.6600130
Koukourakis, 2000, Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer, Cancer Res, 60, 3088
Johnson, 2004, Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer, J Clin Oncol, 22, 2184, 10.1200/JCO.2004.11.022
Herbst, 2005, Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotonib for patients with recurrent non-small-cell lung cancer, J Clin Oncol, 23, 2544, 10.1200/JCO.2005.02.477
Lee, 2005, Multitargeted kinase inhibitors in non-small-cell lung cancer, Oncol Brief, 3, 1
Raefsky, 2005, Irinotecan (I), carboplatin (C), and radiotherapy (RT) followed by bevacizumab (B) in the treatment of limited-stage small cell lung cancer (SCLC), Proc Am Soc Clin Oncol, 7050a, 10.1200/jco.2005.23.16_suppl.7050
Heymach, 2004, ZD6474, a novel antiangiogenic agent, in combination with docetaxel in patients with NSCLC, Proc Am Soc Clin Oncol, 3051a, 10.1200/jco.2004.22.14_suppl.3051
Heymach, 2005, A randomized, placebo-controlled phase II trial of ZD6474 plus docetaxel in patients with NSCLC, Proc Am Soc Clin Oncol, 3023a, 10.1200/jco.2005.23.16_suppl.3023
Herbst, 2005, ZD6474 plus docetaxel in patients with previously treated NSCLC, Lung Cancer, 49, S35, 10.1016/S0169-5002(05)80234-X
Cohen, 2004, Phase I trial of oral CP-547,632 (VEGFR2) in combination with paclitaxel (P) and carboplatin (C) in advanced non-small cell lung cancer (NSCLC), Proc Am Soc Clin Oncol, 3014a, 10.1200/jco.2004.22.14_suppl.3014
Weidner, 1991, Tumor angiogenesis and metastasis –correlation in invasive breast carcinoma, N Engl J Med, 324, 1, 10.1056/NEJM199101033240101
Gasparini, 1997, Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma, J Natl Cancer Inst, 89, 139, 10.1093/jnci/89.2.139
Ragaz, 2004, Adverse association of expressed vascular endothelial growth factor (VEGF), Her2, Cox2, uPA and EMSY with long-term outcome of stage I-III breast cancer (BrCa). Results from the British Columbia Tissue Microarray Project, Proc Am Soc Clin Oncol, 524a, 10.1200/jco.2004.22.14_suppl.524
Cobleigh, 2003, A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer, Semin Oncol, 30, 117, 10.1053/j.seminoncol.2003.08.013
Burstein, 2002, Phase II trial of the anti-VEGF antibody bevacizumab in combination with vinorelbine for refractory advanced breast cancer, Breast Cancer Res Treat, 76, S115
Ramaswamy, 2003, CTEP-sponsored phase II trial of bevacizumab (Avastin®) in combination with docetaxel (Taxotere) in metastatic breast cancer, Breast Cancer Res Treat, 82, S50
Pegram, 2004, Phase I combined biological therapy of breast cancer using two humanized monoclonal antibodies directed against HER2 proto-oncogene and vascular endothelial growth factor (VEGF), Breast Cancer Res Treat, 88, S124
Dickler, 2004, Phase II trial of erlotonib (OSI-774), an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor, and bevacizumab, a recombinant humanized monoclonal antibody to vascular endothelial growth factor (VEGF), in patients (pts) with metastatic breast cancer (MBC), Proc Am Soc Clin Oncol, 2001a, 10.1200/jco.2004.22.14_suppl.2001
Traina, 2005, A feasibility study of an aromatase inhibitor (AI), letrozole (L), and the antibody to vascular endothelial growth factor (VEGF), bevacizumab (B), in patients with hormone receptor-positive metastatic breast cancer (MBC), Proc Am Soc Clin Oncol, 796a, 10.1200/jco.2005.23.16_suppl.796
Overmoyer, 2004, Phase II trial of neoadjuvant docetaxel with or without bevacizumab in patients with locally advanced breast cancer, Breast Cancer Res Treat, 88, S106
Wedam, 2004, A pilot study to evaluate response and angiogenesis after treatment with bevacizumab in patients with inflammatory breast cancer, Proc Am Soc Clin Oncol, 578a, 10.1200/jco.2004.22.14_suppl.578
Miller, 2002, Phase III trial of capecitabine (Xeloda) plus bevacizumab (Avastin) versus capecitabine alone in women with metastatic breast cancer (MBC) previously treated with an anthracycline and a taxane, Breast Cancer Res Treat, 76, S37
Hillan, 2003, The role of VEGF expression in response to bevacizumab plus capecitabine in metastatic breast cancer (MBC), Proc Am Soc Clin Oncol, 766a